Q: What is “Regeneration-Inducing Medicine™”?

A:

This drug is based on a novel mechanism that promotes healing from injuries and illnesses by activating endogenous stem cells through the administration of chemically synthesized peptides. The underlying mechanism was elucidated by our Scientific Founder and Director, Dr. Katsuto Tamai.

Q: What types of diseases is it expected to be effective for?

A:

There is potential to treat a wide range of diseases and tissue damage for which stem cell-based therapies have shown efficacy. The Regeneration-Inducing Medicine™ “Redasemtide,” which has been out-licensed to Shionogi & Co., Ltd., has advanced to the clinical trial stage and is currently in Phase II clinical trials for epidermolysis bullosa, acute ischemic stroke, cardiomyopathy, osteoarthritis of the knee, and chronic liver disease.

Q: What is your current cash burn rate?

A:

As of the end of January 2025, our cash burn rate was ¥124 million per month, and we have secured sufficient operating capital through 2028. We will continue to implement an appropriate financial strategy while taking capital efficiency into consideration.

Q: What differentiates your approach from conventional regenerative medicine and cell therapy?

A:

(1) high safety, (2) cost-effectiveness, and (3) superiority in quality control.

Our Regeneration-Inducing Medicine™ leverages the patient’s own endogenous stem cells and does not require ex vivo cell culture. As a result, the risks of immune rejection and tumorigenesis—issues sometimes observed in certain cell-based therapies—are minimized. Furthermore, unlike cell therapies that require specialized facilities for harvesting, culturing, and storing cells, our compound-based drug can be produced through industrial-scale, planned manufacturing. This enables efficient production, quality control, and distribution at significantly lower cost.

Q: Could you tell us about your IR activities?

A:

We disclose press releases via the Tokyo Stock Exchange’s TDnet platform as well as on our official website. In addition, updates are shared through our official X (formerly Twitter) account.

We also hold financial results briefings twice a year (in March and September) for institutional investors and analysts, and the recordings and materials from these sessions are made available on our website. Moving forward, we will continue to enhance our investor communications by regularly holding financial briefings and expanding the content of our IR materials. We also plan to improve the clarity and accessibility of our information by incorporating feedback from our investors.